American Society of Hematology Annual Meeting

Tecvayli Outcomes Similar in Clinic And Trials for R/R Myeloma

December 9th 2023, 11:06pm

Article

Research demonstrated comparable outcomes in the real-world setting and in the phase 2 MajesTEC-1 trial when it came to treatment with Tecvayli for relapsed or refractory myeloma.

All-Oral Regimen Demonstrates Survival Benefits, Safety in AML Subset

December 9th 2023, 8:39pm

Article

Treatment with an all-oral regimen led to three-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia, a subset of acute myeloid leukemia.

Novel Drug May Provide New Treatment Option for Pretreated Relapsed-Refractory Lymphoma

December 26th 2022, 2:00pm

Article

Data demonstrate that iberdomide alone or in combination with other treatments may be a promising option for patients with relapsed/refractory lymphoma.

Three-Drug Regimen After Transplant May Improve Relapse-Free Survival in GVHD

December 19th 2022, 2:00pm

Article

Adults with graft-versus-host disease who were treated with a three-drug regimen with cyclophosphamide after transplant may have improved survival rate compared with those treated with a two-drug regimen.

Survival and Treatment Response May Be Further Improved With Brukinsa Versus Imbruvica for CLL/SLL

December 14th 2022, 8:00pm

Article

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

Calquence Tends to Be a Shorter-Lived Frontline Regimen Than Imbruvica for Leukemia Subtype

December 13th 2022, 10:00pm

Article

Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.

Upfront Darzalex Combo May Be More Beneficial in the First-Line Setting for Transplant-Ineligible Myeloma Than Alternatives

January 5th 2022, 5:00pm

Article

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

CAR-T Cell Therapy Continues to Impress in Myeloma Treatment

December 15th 2021, 7:00pm

Article

Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial.

Venclexta-Triplet Combo Appears Safe And Shows Deep Responses in Type of Relapsed/Refractory Multiple Myeloma

December 15th 2021, 2:00pm

Article

Two different doses of Venclexta combined with Darzalex and the steroid dexamethasone elicited effective responses appeared safe in patients with t(11;14) relapsed/refractory multiple myeloma.

Imbruvica And Rituxan Bests Standard-of-Care Regimen in Patients With Previously Untreated CLL

December 14th 2021, 2:00pm

Article

The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.